bioRxiv / medRxiv
open access
Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly
BackgroundTirzepatide is conventionally initiated at 2.5 mg weekly and titrated to approved maintenance doses. Evidence describing weight change at injectable starting doses below 2.5 mg/week is limited. MethodsWe conducted a retrospective, single-organization observational study of adults document
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss#424333
- A Study of Tirzepatide in Overweight and Very Overweight Participants#1370251
- A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants#1089233
- Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide#657802
- A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body#858642
Record · ID 1361648
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive